Abstract
BackgroundHigh-intensity ultrasound has been used to induce acoustic cavitation in the skin and subsequently enhances skin permeability to deliver hydrophobic topical medications including lidocaine. In contrast, instead of changing skin permeability, pulsed application of low-intensity focused ultrasound (FUS) has shown to non-invasively and temporarily disrupt drug-plasma protein binding, thus has potential to enhance the anesthetic effects of hydrophilic lidocaine hydrochloride through unbinding it from serum/interstitial α1-acid glycoprotein (AAG).MethodsFUS, operating at fundamental frequency of 500 kHz, was applied pulse-mode (55-ms pulse duration, 4-Hz pulse repetition frequency) at a spatial-peak pulse-average intensity of 5 W/cm2. In vitro equilibrium dialysis was performed to measure the unbound concentration of lidocaine (lidocaine hydrochloride) from dialysis cassettes, one located at the sonication focus and the other outside the sonication path, all immersed in phosphate-buffered saline solution containing both lidocaine (10 µg/mL) and human AAG (5 mg/mL). In subsequent animal experiments (Sprague-Dawley rats, n = 10), somatosensory evoked potential (SSEP), elicited by electrical stimulations to the unilateral hind leg, was measured under three experimental conditions—applications of FUS to the unilateral thigh area at the site of administered topical lidocaine, FUS only, and lidocaine only. Skin temperature was measured before and after sonication. Passive cavitation detection was also performed during sonication to evaluate the presence of FUS-induced cavitation.ResultsSonication increased the unbound lidocaine concentration (8.7 ± 3.3 %) from the dialysis cassette, compared to that measured outside the sonication path (P < 0.001). Application of FUS alone did not alter the SSEP while administration of lidocaine reduced its P23 component (i.e., a positive peak at 23 ms latency). The FUS combined with lidocaine resulted in a further reduction of the P23 component (in a range of 21.8 − 23.4 ms after the electrical stimulations; F(2,27) = 3.2 − 4.0, P < 0.05), indicative of the enhanced anesthetic effect of the lidocaine. Administration of FUS neither induced cavitation nor altered skin conductance or temperature, suggesting that skin permeability was unaffected.ConclusionsUnbinding lidocaine from the plasma proteins by exposure to non-thermal low-intensity ultrasound is attributed as the main mechanism behind the observation.
Highlights
High-intensity ultrasound has been used to induce acoustic cavitation in the skin and subsequently enhances skin permeability to deliver hydrophobic topical medications including lidocaine
The temperature did not change with time (24.39 ± 0.06 °C across 7 time points; one-way repeated measures analysis of variance [Analysis of variance (ANOVA)], F(6,54) = 1.64, P = 0.16) and Evaluation of cavitation A passive cavitation detection technique was used to examine the presence of any cavitation by measuring the acoustic emission spectra associated with sonication [35, 36]
There was no difference in skin conductance (ΔGSR) before, during, and after focused ultrasound (FUS) sonication (one-way repeated measures ANOVA, F(2, 18) = 1.2, P = 0.31; -1.5 ± 2.9, -0.8 ± 1.5, and − 1.4 ± 2.2 μS)
Summary
High-intensity ultrasound has been used to induce acoustic cavitation in the skin and subsequently enhances skin permeability to deliver hydrophobic topical medications including lidocaine. Instead of changing skin permeability, pulsed application of low-intensity focused ultrasound (FUS) has shown to noninvasively and temporarily disrupt drug-plasma protein binding, has potential to enhance the anesthetic effects of hydrophilic lidocaine hydrochloride through unbinding it from serum/interstitial α1-acid glycoprotein (AAG). Lidocaine acts on peripheral nerves by reversibly blocking sodium channels on the cell membrane, thereby inhibiting depolarization. Lidocaine has been used as local anesthetics and nerve blocking agents, as well as to treat ventricular tachycardia [1,2,3]. Cutaneous administration of hydrophilic lidocaine hydrochloride, available in various forms of delivery, is widely used to provide temporary relief of muscle or peripheral pain. Efforts have been made to improve its delivery; e.g., through the use of vehicles such as liposome [6], needleless gas-based transcutaneous injector [7], and iontophoresis by application of electrical currents to the skin [8]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.